Immunotherapy biotech Apellis Pharmaceuticals sets terms for $150 million IPO – Nasdaq
|
Immunotherapy biotech Apellis Pharmaceuticals sets terms for $150 million IPO
Nasdaq Apellis Pharmaceuticals, which is developing a novel protein inhibitor for autoimmune and inflammatory diseases, announced terms for its IPO on Monday. The Crestwood, KY-based company plans to raise $150 million by offering 10.7 million shares at a … |
